Do analysts rate CASI or HEPA?

CASI Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate TRIB or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate QLGN or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, QLGN or HEPA?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is QLGN or HEPA more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Hepion Pharmaceuticals N/A -812.56% -207.31%

Do analysts prefer ELAB or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ELAB or HEPA more profitable?

PMGC's return on equity of -117.82% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% Hepion Pharmaceuticals N/A -812.56% -207.31%

Do analysts rate HEPA or CANF?

Can-Fite BioPharma has a consensus target price of $42.50, suggesting a potential upside of 1,244.94%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is HEPA or CANF more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Can-Fite BioPharma N/A N/A N/A

Hepion Pharmaceuticals (HEPA) Competitors

$0.06 +0.00 (+3.33%)

As of 02:08 PM Eastern

Compare

HEPA vs. CASI, TRIB, QLGN, ELAB, and CANF

Should you buy Hepion Pharmaceuticals stock or one of its competitors? MarketBeat compares Hepion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hepion Pharmaceuticals include CASI Pharmaceuticals (CASI), Trinity Biotech (TRIB), Qualigen Therapeutics (QLGN), PMGC (ELAB), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry.

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Hepion Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

CASI Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Hepion Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

CASI Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CASI Pharmaceuticals is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CASI Pharmaceuticals beats Hepion Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Trinity Biotech?

Trinity Biotech (NASDAQ:TRIB) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Hepion Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%. Trinity Biotech's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-85.36%	N/A	-36.61%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Trinity Biotech has higher revenue and earnings than Hepion Pharmaceuticals. Trinity Biotech is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.06	-$37.38M	-$3.90	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, Trinity Biotech's average media sentiment score of 1.89 beat Hepion Pharmaceuticals' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Trinity Biotech	Very Positive
Hepion Pharmaceuticals	Neutral

Summary

Trinity Biotech beats Hepion Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:QLGN) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Hepion Pharmaceuticals	Neutral

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Qualigen Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Qualigen Therapeutics beats Hepion Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to PMGC?

PMGC (NASDAQ:ELAB) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

PMGC's return on equity of -117.82% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

In the previous week, PMGC had 4 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 4 mentions for PMGC and 0 mentions for Hepion Pharmaceuticals. PMGC's average media sentiment score of 0.73 beat Hepion Pharmaceuticals' score of 0.00 indicating that PMGC is being referred to more favorably in the media.

Company	Overall Sentiment
PMGC	Positive
Hepion Pharmaceuticals	Neutral

PMGC has higher revenue and earnings than Hepion Pharmaceuticals. PMGC is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$590K	3.32	-$7.75M	-$168.62	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

PMGC has a beta of -0.27, meaning that its share price is 127% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

22.2% of PMGC shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 0.0% of PMGC shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PMGC beats Hepion Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Can-Fite BioPharma?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Can-Fite BioPharma's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Can-Fite BioPharma	N/A	N/A	N/A

In the previous week, Can-Fite BioPharma had 3 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.34 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
Can-Fite BioPharma	Neutral

Can-Fite BioPharma has higher revenue and earnings than Hepion Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Can-Fite BioPharma	$405K	5.11	-$7.63M	-$35.80	N/A

Hepion Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Can-Fite BioPharma has a consensus target price of $42.50, suggesting a potential upside of 1,244.94%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Can-Fite BioPharma beats Hepion Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEPA vs. The Competition

Export

Metric	Hepion Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$709K	$993.40M	$6.44B	$12.46B
Dividend Yield	N/A	4.84%	2.69%	5.22%
P/E Ratio	-0.01	1.49	23.87	24.36
Price / Sales	N/A	125.49	521.52	117.07
Price / Cash	N/A	20.06	41.27	57.13
Price / Book	0.05	8.12	9.99	6.73
Net Income	-$48.93M	-$3.91M	$3.56B	$337.03M
7 Day Performance	N/A	-1.72%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	N/A	111.96%	28.77%	33.98%

Hepion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEPA Hepion Pharmaceuticals	N/A	$0.06 +3.3%	N/A	+48.5%	$709K	N/A	N/A	20	Gap Up
CASI CASI Pharmaceuticals	0.9892 of 5 stars	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180	News Coverage
TRIB Trinity Biotech	0.6163 of 5 stars	$0.71 -3.0%	N/A	-77.9%	$2.55M	$43.79M	N/A	480	Positive News Gap Up
QLGN Qualigen Therapeutics	N/A	$1.26 -3.8%	N/A	-67.6%	$2.14M	N/A	N/A	50
ELAB PMGC	0.2381 of 5 stars	$1.79 +6.5%	N/A	-99.0%	$2.07M	$1.27M	N/A	18	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. CASI, TRIB, QLGN, ELAB, and CANF

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Summary

How does Hepion Pharmaceuticals compare to Trinity Biotech?

Summary

How does Hepion Pharmaceuticals compare to Qualigen Therapeutics?

Summary

How does Hepion Pharmaceuticals compare to PMGC?

Summary

How does Hepion Pharmaceuticals compare to Can-Fite BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. CASI, TRIB, QLGN, ELAB, and CANF

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Is CASI or HEPA more profitable?

Which has preferable earnings & valuation, CASI or HEPA?

Which has more risk and volatility, CASI or HEPA?

Does the media favor CASI or HEPA?

Do analysts rate CASI or HEPA?

Do institutionals and insiders hold more shares of CASI or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Trinity Biotech?

Do analysts rate TRIB or HEPA?

Is TRIB or HEPA more profitable?

Do insiders and institutionals hold more shares of TRIB or HEPA?

Which has better valuation and earnings, TRIB or HEPA?

Does the media refer more to TRIB or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Qualigen Therapeutics?

Does the media favor QLGN or HEPA?

Which has preferable valuation & earnings, QLGN or HEPA?

Do analysts rate QLGN or HEPA?

Which has more volatility & risk, QLGN or HEPA?

Is QLGN or HEPA more profitable?

Do institutionals and insiders hold more shares of QLGN or HEPA?

Summary

How does Hepion Pharmaceuticals compare to PMGC?

Is ELAB or HEPA more profitable?

Does the media favor ELAB or HEPA?

Which has better valuation and earnings, ELAB or HEPA?

Which has more volatility and risk, ELAB or HEPA?

Do institutionals and insiders believe in ELAB or HEPA?

Do analysts prefer ELAB or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Can-Fite BioPharma?

Is HEPA or CANF more profitable?

Does the media prefer HEPA or CANF?

Which has better earnings and valuation, HEPA or CANF?

Which has more volatility & risk, HEPA or CANF?

Do insiders & institutionals have more ownership in HEPA or CANF?

Do analysts rate HEPA or CANF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools